Larimar Therapeutics Inc

LRMR is in a Stage 4 decline with price making lower highs and lower lows beneath declining EMAs. The medium-term bias is bearish, and short-term behavior shows rejection at the 9/21 EMA zone, presenting an immediate sell opportunity. Support remains absent until price can reclaim intermediate moving averages, so selling into the current bounce is warranted.

• ↑Cash reserves of ~$178M with minimal debt secure runway into 2027.
• ↑First BLA module submitted for nomlabofusp; sustained frataxin levels noted.
• ↓Anaphylaxis in 10/41 patients raises regulatory approval risk.